The Enbrel space

It's no secret that Immunex Corp. can't make enough of its Enbrel etanercept rheumatoid arthritis drug to meet demand. With every passing day, there is the potential that new patients will start taking the one competing anti-TNF drug, Johnson & Johnson's Remicade anti-TNF chimeric monoclonal antibody, which is approved for both RA and Crohn's disease.

IMNX also faces the possibility that it won't

Read the full 638 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE